Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
K. Jhaveri, L. D. Eli, H. Wildiers, S. A. Hurvitz, A. Guerrero-Zotano, N. Unni, A. Brufsky, H. Park, J. Waisman, E. S. Yang, I. Spanggaard, S. Reid, M. E. Burkard, S. Vinayak, A. Prat, M. Arnedos, F. C. Bidard, S. Loi, J. Crown, M. BhaveS. A. Piha-Paul, J. M. Suga, S. Chia, C. Saura, J. Garcia-Saenz, V. Gambardella, M. J. de Miguel, E. N. Gal-Yam, A. Rapael, S. M. Stemmer, C. Ma, A. B. Hanker, D. Ye, J. W. Goldman, R. Bose, L. Peterson, J. S.K. Bell, A. Frazier, D. DiPrimeo, A. Wong, C. L. Arteaga, D. B. Solit
Dive into the research topics of 'Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial'. Together they form a unique fingerprint.